Skip to search formSkip to main contentSkip to account menu

etoricoxib

Known as: 5-chloro-2-(6-Methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine, 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl, 5-chloro-6'-Methyl-3-(P-(methylsulfonyl)phenyl)-2,3'-bipyridine 
A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (2)

ArcoxiaMK 0663

Broader (3)

Cyclooxygenase 2 InhibitorsPyridinesSulfones
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Effect of iNOS inhibitor S-methylisothiourea in monosodium iodoacetate-induced osteoathritic pain: Implication for osteoarthritis therapy
2012
2012
An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database
To identify practices common to both the General Practice Research Database and The Health Improvement Network database for… 
Highly Cited
2011
Highly Cited
2011
Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the Postoperative Dental Pain Model
ObjectiveThis study was conducted to evaluate the dose range of etoricoxib in acute pain using the postoperative dental pain… 
2009
2009
Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines
Background  Protective co‐therapy is recommended in NSAID users with GI risk factors, but adherence is poor. 
2008
2008
Trypanosoma cruzi: the role of PGE2 in immune response during the acute phase of experimental infection.
Review
2008
Review
2008
Positioning dual inhibitors in the treatment of pain and inflammatory disorders
2006
2006
Do selective COX‐2 inhibitors increase the risk of cerebrovascular events? A meta‐analysis of randomized controlled trials
Objectives:  To evaluate the risk of cerebrovascular events (CVEs) associated with selective cyclooxygenase‐2 inhibitors (coxibs… 
Review
2006
Review
2006
Systematic review: coxibs, non‐steroidal anti‐inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high‐risk patients?
Selective cyclooxygenase‐2 inhibitors have been marketed as alternatives of conventional, non‐steroidal anti‐inflammatory drugs… 
Highly Cited
2005
Highly Cited
2005
Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats.
BACKGROUND The purpose of the present study was to evaluate the effect of a potent selective cyclooxygenase-2 (COX-2) inhibitor… 
Highly Cited
2003
Highly Cited
2003
Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor
Etoricoxib is a potent selective COX‐2 inhibitor in man. Ex vivo whole‐blood assays assessed COX‐2 inhibition after oral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)